MDRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MDRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Veradigm's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $0.12. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $0.41.
Veradigm's EPS (Basic) for the three months ended in Sep. 2022 was $0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $0.50.
Veradigm's EPS without NRI for the three months ended in Sep. 2022 was $0.23. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $1.19.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
The historical data trend for Veradigm's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veradigm Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
EPS (Diluted) | Get a 7-Day Free Trial | -1.09 | 2.07 | -1.10 | 4.40 | 0.97 |
Veradigm Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
EPS (Diluted) | Get a 7-Day Free Trial | 0.12 | 0.68 | 0.17 | -0.56 | 0.12 |
For the Health Information Services subindustry, Veradigm's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's PE Ratio distribution charts can be found below:
* The bar in red indicates where Veradigm's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Veradigm's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as
Diluted EPS (A: Dec. 2021 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (134.438 | - | 0) | / | 138.658 | |
= | 0.97 |
Veradigm's Diluted EPS for the quarter that ended in Sep. 2022 is calculated as
Diluted EPS (Q: Sep. 2022 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (14.528 | - | 0) | / | 128.871 | |
= | 0.11 |
EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veradigm (OTCPK:MDRX) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Veradigm's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Shih Yin Ho | director | 222 MERCHANDISE MART, SUITE 2024, CHICAGO IL 60654 |
Susan Rodriguez | director | C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555 |
Richard J. Poulton | officer: CFO | 3646 WESTFIELD LANE, GLENVIEW IL 60026 |
Tejal Vakharia | officer: SVP Gerneral Counsel | 222 MERCHANDISE MART PLZ, SUITE 2024, CHICAGO IL 60654 |
David B Stevens | director | 1 IMATION WAY, OAKDALE MN 55128 |
Leah Jones | officer: Chief Financial Officer | 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654 |
Paul Black | director | 400 WOOD ROAD, BRAINTREE MA 02184 |
Elizabeth Ann Altman | director | 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121 |
Thomas Langan | officer: President and CCO | 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654 |
Lisa Hammond | officer: SVP & Chief HR Officer | 305 CHURCH AT NORTH HILLS STREET, RALEIGH NC 27609 |
Greg Garrison | director | 222 MERCHANDISE MART PLAZA, CHICAGO IL 60654 |
Lisa Khorey | officer: Chief Client Delivery Officer | 222 MERCHANDISE MART PLAZA, CHICAGO IL 60654 |
Michael Klayko | director | |
Carol J Zierhoffer | director | 100 NORTH POINT CENTER EAST, SUITE 200, ALPHARETTA GA 30022 |
Brian Farley | officer: SVP Gerneral Counsel & Corpora | 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654 |
From GuruFocus
By PRNewswire • 01-06-2024
By PRNewswire • 01-07-2024
By PRNewswire • 12-29-2023
By Business Wire • 01-09-2024
By PRNewswire • 01-19-2024
By PRNewswire • 01-02-2024
By PRNewswire • 01-14-2024
By PRNewswire • 01-11-2024
By Business Wire • 01-19-2024
By PRNewswire • 01-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.